Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer-Reference-Cited by-同舟云学术

Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer

Published:2005-07 Issue:5 Volume:4 Page:4-13
ISSN:1569-9056
Container-title:European Urology Supplements
language:en
Short-container-title:European Urology Supplements

Author:

Mongiat-Artus P.,Teillac P.

Publisher

Elsevier BV

Subject

Urology

Reference90 articles.

1. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland;Huggins;Arch Surg,1941

2. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies;Byar;NCI Monogr,1988

3. Androgen receptor: an overview;Chang;Crit Rev Eukaryot Gene Expr,1995

4. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice;Koppan;Prostate,1999

5. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop;Dondi;Cancer Res,1994

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel multifunctional nanocarrier-mediated codelivery for targeting and treatment of prostate cancer;Nanomaterials for Drug Delivery and Therapy;2019

2. Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice;Journal of Urology;2018-01

3. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy;BJU International;2009-02

4. Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy;Journal of Urology;2007-10

5. Luteinising hormone-releasing hormone antagonists in prostate cancer therapy;Expert Opinion on Emerging Drugs;2007-05